Filtered By:
Drug: Empagliflozin
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 127 results found since Jan 2013.
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) Inhibitors
N Z Med J. 2022 Aug 19;135(1560):99-104.ABSTRACTThe sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure, progressive kidney dysfunction, myocardial infarction, stroke and gout. Patients with or without diabetes who have a history of heart failure, including those with a preserved left ventricular ejection fraction and patients with ch...
Source: New Zealand Medical Journal - August 24, 2022 Category: General Medicine Authors: Chok G Chan Ralph Stewart Source Type: research
E-094 Trends in endovascular treatment of cervical artery dissections: a nationwide analysis
ConclusionsDespite an increase in the overall use of endovascular therapy for the treatment of cervical artery dissection in patients with ischemic stroke or TIA, there was no significant association with early clinical outcomes. Future studies looking at long term outcomes including stroke-recurrence are warranted.Disclosures M. Bouslama: None. C. Zhang: None. H. Kamel: 1; C; PI for the NIH-funded ARCADIA trial (NINDS U01NS095869) which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis® and ancillary study support from Roche Diagnostics. 2; C; Deputy Editor for JAMA Neurology, steering committee mem...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Bouslama, M., Zhang, C., Kamel, H., Merkler, A. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study
CONCLUSION: As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin.PRIMARY FUNDING SOURCE: Brigham and Women's Hospital and Harvard Medical School.PMID:35605236 | DOI:10.7326/M21-4012
Source: Annals of Internal Medicine - May 23, 2022 Category: Internal Medicine Authors: HoJin Shin Sebastian Schneeweiss Robert J Glynn Elisabetta Patorno Source Type: research
Effect of a low dose of empagliflozin on short-term outcomes in type 2 diabetics with acute coronary syndrome after percutaneous coronary intervention
CONCLUSION: The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.PMID:35537720 | DOI:10.15537/smj.2022.43.5.20220018
Source: Saudi Medical Journal - May 10, 2022 Category: Middle East Health Authors: Seyed Mohammad H Adel Fateme Jorfi Hoda Mombeini Homeira Rashidi Saad Fazeli Source Type: research
